Two Sigma Investments LP decreased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 91.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,400 shares of the biopharmaceutical company’s stock after selling 185,558 shares during the quarter. Two Sigma Investments LP’s holdings in Vanda Pharmaceuticals were worth $280,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Armistice Capital LLC boosted its stake in shares of Vanda Pharmaceuticals by 74.8% in the fourth quarter. Armistice Capital LLC now owns 2,678,000 shares of the biopharmaceutical company’s stock worth $40,706,000 after buying an additional 1,146,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Vanda Pharmaceuticals by 17.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,434,850 shares of the biopharmaceutical company’s stock worth $21,810,000 after buying an additional 216,600 shares during the last quarter. Stonepine Capital Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 195.0% in the fourth quarter. Stonepine Capital Management LLC now owns 885,000 shares of the biopharmaceutical company’s stock worth $13,452,000 after buying an additional 585,000 shares during the last quarter. University of Notre Dame DU Lac boosted its stake in shares of Vanda Pharmaceuticals by 28.2% in the fourth quarter. University of Notre Dame DU Lac now owns 202,230 shares of the biopharmaceutical company’s stock worth $3,074,000 after buying an additional 44,449 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Vanda Pharmaceuticals in the fourth quarter worth about $672,000. Hedge funds and other institutional investors own 81.04% of the company’s stock.
In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 8,532 shares of the stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $18.72, for a total transaction of $159,719.04. Following the transaction, the chief financial officer now owns 208,066 shares in the company, valued at $3,894,995.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mihael Hristos Polymeropoulos sold 60,966 shares of the stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $18.72, for a total value of $1,141,283.52. Following the transaction, the insider now owns 1,243,838 shares in the company, valued at approximately $23,284,647.36. The disclosure for this sale can be found here. Insiders have sold 78,023 shares of company stock worth $1,460,591 in the last quarter. 7.60% of the stock is currently owned by company insiders.
VNDA has been the topic of a number of recent research reports. Oppenheimer restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, March 22nd. BidaskClub downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 17th. Seaport Global Securities reiterated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 28th. Jefferies Group reiterated a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, February 13th. Finally, ValuEngine upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. Vanda Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $21.67.
Shares of VNDA stock opened at $15.25 on Thursday. The company has a market cap of $759.09, a price-to-earnings ratio of -43.57 and a beta of 1.12. Vanda Pharmaceuticals Inc. has a 12-month low of $11.90 and a 12-month high of $20.40.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The company had revenue of $44.28 million for the quarter, compared to the consensus estimate of $44.00 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. Vanda Pharmaceuticals’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.08 earnings per share. equities analysts forecast that Vanda Pharmaceuticals Inc. will post -0.09 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Two Sigma Investments LP Sells 185,558 Shares of Vanda Pharmaceuticals Inc. (VNDA)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/19/two-sigma-investments-lp-sells-185558-shares-of-vanda-pharmaceuticals-inc-vnda.html.
Vanda Pharmaceuticals Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.